Imugene Limited (ASX:IMU)
Australia
· Delayed Price · Currency is AUD 0.0380
-0.0010 (-2.56%)
Feb 21, 2025, 4:10 PM AEST
Imugene Revenue
In the fiscal year ending June 30, 2024, Imugene had annual revenue of 4.97M AUD, down -57.80%. Imugene had revenue of -3.10M in the half year ending June 30, 2024, a decrease of -140.63%.
Revenue
4.97M
Revenue Growth
-57.80%
P/S Ratio
54.21
Revenue / Employee
994.01K
Employees
5
Market Cap
283.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
| Jun 30, 2020 | 4.13M | 6.56K | 0.16% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Telix Pharmaceuticals | 783.21M |
| Ramsay Health Care | 16.66B |
| Ansell | 3.00B |
| Mesoblast | 8.85M |
Imugene News
- 5 months ago - Imugene Ltd Azer-cel Trial Update Transcript - GuruFocus
- 11 months ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 11 months ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 1 year ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 1 year ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 3 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire
- 3 years ago - Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer - GlobeNewsWire